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Abstract
The ultrafiltration failure during peritoneal dialysis (PD) is related to inflammatory 
responses induced by bio-incompatible PD fluids, which may lead to deterioration of 
peritoneal membrane (PM) function. Mesothelial cells, lymphocytes, macrophages and 
other cell types present in the peritoneal cavity are stimulated to produce cytokines and 
growth factors that promote pathological processes. Due to these factors, blood and lym-
phatic vessels proliferate and could be responsible for hyperfiltration and PM failure 
type III and IV. Vessels proliferation may be related to fibrosis, being the cause and/or 
effect of the mesenchymal conversion of different cell types such as mesothelial (MMT), 
bone marrow-derived (fibrocytes) or endothelial (vascular- and lymph-endo-MT) cells. 
Lymphangiogenesis in PD is a poorly analysed process; however, its contribution to 
peritoneal function disorders has been recently recognized. VEGF production is associ-
ated with blood and lymphatic vessels proliferation, while specifically lymphangiogen-
esis is mainly regulated by VEGF-C and VEGF-D. Excessive lymphatic fluid drainage 
from the abdominal cavity may be related with macromolecule and isosmotic solutions 
reuptake and convective reabsorption of solutes that were cleared from plasma by diffu-
sion. Some drugs have been shown to modulate tissue fibrosis, MMT, EndoMT, angio-
genesis and lymphangiogenesis and could represent interesting therapeutic strategies to 
protect the PM.
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1. Introduction
Peritoneal dialysis (PD) is based on the use of the peritoneal membrane (PM) as a semi-per-
meable membrane across which ultrafiltration (UF) and diffusion take place [1], thus allowing 
diffusive exclusion of uraemic toxins and exchange of solutes between circulation and PD 
fluid (PDF) to maintain solute and fluid equilibrium in uraemic patients [2]. However, it has 
also some disadvantages that include the risk of peritonitis, peritoneal tissue remodeling and 
vessels proliferation [3].
The efficacy of PD depends on the structural and functional PM integrity. It consists of a mono-
layer of mesothelial cells (MCs) supported by connective tissue that covers the inner surface 
of the abdominal wall and most visceral organs. During PD, the peritoneum is continuously 
exposed to large volumes of bio-incompatible solutions (hyperosmolar, acidic and with high 
glucose content), leading to morphological and functional alterations of the PM. Furthermore, 
PDFs contain glucose degradation products (GDPs), potentially toxic to the PM [4]. Glucose 
can also contribute to PM alterations through formation of advanced glycation end products 
(AGEs). AGEs can bind with some receptors, such as the receptor of AGEs (RAGE), activating 
intracellular signals that produce oxidative stress and synthesis of inflammatory cytokines [5]. 
All these bio-incompatible features induce an immunological response in the peritoneal cavity 
that involves MCs, macrophages, lymphocytes and neutrophils. When stimulated, these cells 
produce a wide variety of cytokines, chemokines and growth factors, such as tumor necrosis 
factor (TNF)-𝛼, interleukin (IL)-1, IL-6, IL-8, IL-17, transforming growth factor (TGF)-𝛽, vascu-
lar endothelial growth factor (VEGF), fibroblast growth factor (FGF)-2, monocyte chemotactic 
protein (MCP)-1 and many others, therefore increasing inflammation and causing structural 
and functional alterations [6, 7]. Consequently, histology of patients chronically exposed to 
PDFs reveals mesothelial cell loss, increase of the submesothelial extracellular matrix (ECM) 
deposition (fibrosis), angiogenesis and lymphangiogenesis. All these changes are intercon-
nected factors associated with alterations on fluid and solute removal; they ultimately lead to 
different spectra of PM ultrafiltration failure (UFF) types (type I–IV) (Table 1) (Figure 1) [8]. 
Types of 
UFF
Clinical characteristics Anatomic/physiologic bases Actual therapeutic measure
Type I Increased peritoneal exchange 
surface area
PM hyper-permeability Avoid Icodextrin long PD dwells
Type II Low osmotic conductance to 
glucose
AQP-1 channels dysfunction Peritoneal resting and adhesions 
surgery
Type III Diminished peritoneal 
exchange surface area
EPS, abdominal adhesions Peritoneal resting, hypertonic glucose 
or icodextrin long PD dwells
Type IV Increased lymphatic 
absorption rate
Increased lymphatic absorption Avoid large and long volume dwells
Adapted from Prasad and Gupta [8].
Table 1. Clinical characteristics and accepted therapeutic option for UFF.
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Consequently, there is an extracellular volume overload [9, 10], which compromises treat-
ment efficacy and patient outcomes, who have to be transferred to hemodialysis.
Therefore, to improve PM longevity in PD, it is mandatory to diminish or block the up-regulation 
of the molecular mechanisms implicated in the onset of the UFF. Herein, we update the knowl-
edge about the mechanisms implicated in the PM failure, especially those associated with angio-
genesis and lymphangiogenesis, and we propose some therapeutic alternatives.
1.1. PM failure in PD: clinical features
In 1993, B. Rippe described the three-pore model of peritoneal transport [11], according to 
which the main peritoneal exchange route for water and water-soluble substances is a pro-
tein-restrictive pathway (“first pathway”, small pores), accounting for approximately 99% of 
the total exchange area and approximately 90% of the total UF coefficient. For their passage 
through the PM, proteins are confined to the “second pathway” (large pores, extremely few 
in number, about 0.01%), more or less non-restrictive with respect to protein transport. The 
“third pathway” (“water-only, solute-free transport”, ultra-small pores) accounts for about 
2% of the total UF coefficient and is permeable to water but impermeable to solutes, and it has 
been associated to aquaporin (AQP)-1 channels (a membrane protein). Transcellular water 
permeability mediated by AQP-1 is an essential component of the water removal across the 
PM. Studies in AQP-1 KO mice confirmed that AQP-1 is responsible for approximately 50% 
of the UF when using a crystalloid osmotic agent such as glucose, and that its expression is 
necessary to observe the sodium sieving [12].
The UF rate has been linked with high survival in a prospective observational study (EAPOS 
study). Besides, UF was also predictive of survival in anuric automated PD patients [13]. 
Although in this report the authors did not find association with survival when analysing 
time-averaged UF (time dependently), in another study (NECOSA-D study) a time-dependent 
survival relationship was found [14]. Although UFF can occur at any stage, it usually happens 
in long-term PD. The first studies reported an accumulative risk for permanent loss of net UF 
capacity to be 2.6% at first year, 9.5% after 3 years, and more than 30% for patients on CAPD 
[8]. In 2000, the International Society for Peritoneal Dialysis (ISPD) committee performed a 
Figure 1. Characteristics of the different types of UFF.
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standardized test using a 3.86 /4.25% glucose exchange with 4 h of permanence. They defined 
a net UF of <400 mL after a four hours’ dwell. Based on this criterion, new studies have dem-
onstrated that UFF prevalence is between 23 and 36% [8] (Figure 1).
UFF is an increased complication in long-term PD patients associated with fluid overload, 
mainly when associated with high solute peritoneal transport. The importance of UFF is related 
to the increased cardiovascular mortality [15]. UFF could be explained by a combination of two 
processes occurring in parallel: changes in vascularization and production of fibrotic tissue in 
the PM [12]. Four types of UFF have been defined according to their specific features.
1.1.1. Type I UFF
High solute transport, with a dialysate-to-plasma ratio (D/P) of creatinine >0.81. It represents 
the largest UFF type and usually happens during/after peritonitis episodes. PM shows an 
inflammatory process with subsequent hyper-permeability. The anatomical status is probably 
the result of both tissue fibrosis and angiogenesis resulting in a large effective exchange sur-
face area. Angiogenesis leads to an increased number of perfused capillaries under the fibrotic 
matrix, which rapidly dissipate the glucose-driven osmotic pressure. This hyper-permeability 
has been demonstrated as a predictor of increase in mortality [13]. The uraemic state itself pro-
longs the exposure to glucose and GDPs and increases the cumulative effects of inflammation. 
These, in turn, are associated with angiogenesis with leaky capillaries, culminating in increased 
effective peritoneal surface area and rapid solute transport with diminished UF capacity [14].
1.1.2. Type II UFF
AQP-l dysfunction; low/high average solute transport, D/P of creatinine = 0.5–0.8. The trans-
capillary movement of free water via AQP-1 accounts for 40 to 50% of total UF across the PM 
[16, 17]. This UFF is characterized by an increase in solute transport (for creatinine or glucose), 
residual volume, or lymphatic absorption. However, it has been reported that in these patients 
normal sodium sieving effect (drop in dialysate sodium concentration) is lost [18]. This selec-
tive defect attributed to AQP-l channels dysfunction is responsible of water transport failure 
rather than structural PM injuries [19]. Its cause has been not yet elucidated, but there is rel-
evant information pointing to the roles of glycosylation or endothelial nitric oxide. Moreover, 
the PM AQP-1 expression can be up-regulated [20]. Free water transport can be estimated by 
subtracting the UF through small pores from the total UF over a period of 1 h, and with this 
method, free water transport ≤26% of total UF is consistent with impaired AQP-1 function [17].
1.1.3. Type III UFF
Patients with low solute transport rates (D/P creatinine <0.5). This is the less common cause for 
UFF. Anatomically, there is a severe reduction in effective PM surface area and permeability 
[21]. Clinically, these patients may therefore present signs of volume overload, symptoms of 
inadequate solute removal, or both. The diffuse hypo-permeability of the PM may be caused by 
the effects of pro-fibrotic mediators such as TGF-β and as a consequence of a process of mesothe-
lial to mesenchymal transition suffered by MCs (MMT) [6, 22]. This is observed in patients who 
have recurrent and relapsing peritonitis, sclerosis of PM (sclerosing peritonitis), and extensive 
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intra-abdominal adhesions [22]. In early stages (simple peritoneal sclerosis), there is a dimi-
nution in peritoneal transport without serious clinical consequences. In advanced conditions, 
encapsulating peritoneal sclerosis (EPS) may be developed; it is a clinical syndrome character-
ized by bowel obstruction through persistent PM adhesions frequently associated to calcification 
[23]. This complication leads to a high mortality due to intestinal obstruction and malnutrition.
1.1.4. Type IV UFF
Alterations in dialysate solute concentrations. The D/P creatinine ratio does not change with 
increased lymphatic flow, although net UF can be considerably reduced. Increased lymphatic 
flow, net UF and solute clearance are inversely related to lymphatic fluid absorption [22]. This 
represents no more than 10–30% of the total fluid absorbed via lymphatic vessels [24]. The 
estimation of fluid loss may be done by examining the egress rate of radio-labeled albumin 
from the peritoneal cavity (averages 1.52 ml/min, with 2 L exchange) [25]. Factors influencing 
lymphatic absorption are dialysate volume, intraperitoneal pressure and mass transfer area 
coefficient of PM. Factors not influencing lymphatic absorption are body surface area, tonicity 
of the dialysate, position of the patient and probably duration of PD. The pathogenesis of this 
UFF type is poorly understood. It has been suggested that TGF-β1 may play a role in promot-
ing lymphangiogenesis in a rat model [9].
2. Fibrogenic capacity of peritoneal populations
Fibroblastic-like cells may originate from different sources in the peritoneal matrix, collaborat-
ing in the fibrotic process that leads to PM malfunction. These cells are able to produce ECM 
components and acquire the ability to produce inflammatory, fibrogenic and angiogenic factors.
Well-known cells that may overcome a mesenchymal transition as a consequence of PDFs 
bio-incompatibility, acquiring a fibroblastoid phenotype, are the mesothelial cells lining the 
peritoneal membrane (suffering MMT) [26]. MMT is a complex process characterized by the 
disruption of intercellular junctions, loss of apical-basolateral polarity and acquisition of 
migratory and invasive properties. During the MMT, there is a strong up-regulation of VEGF 
and TGF-𝛽 in the peritoneum, which provides enhancement of the local vascular networks, 
leading to vessel proliferation [27]. Cells that undergo a mesenchymal transition acquire mes-
enchymal markers, including alpha smooth muscle actin (α-SMA), fibroblast-specific protein 
1 (FSP-1) and fibronectin [28–30]. It has been described that even a 37% of fibroblastic-like 
cells present in the injured peritoneum of PD patients can derive from MCs that have undergo 
MMT as a consequence of PDFs exposure [30].
Additionally, there are other cell populations in the peritoneum that may also undergo a mes-
enchymal transition and collaborate in fibrotic diseases and specifically in PD-related fibrosis, 
as inflammatory bone marrow-derived circulating cells (fibrocytes), that could represent a 
34% of total FSP1+ fibroblasts, and endothelial cells from blood vessels (endo-MT) (approxi-
mately 5%) [27, 29–33]. Besides TGF-β, it has been shown that endothelin-1 (ET-1) may also 
participate in endo-MT [28]. Interestingly, adipose tissue macrophages can experiment a mes-
enchymal transition [34]. Moreover, it has been recently observed that endothelial cells from 
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lymphatic vessels may also suffer a partial endothelial-mesenchymal transition [35]. Other 
studies also pointed to a mesenchymal status of lymphatic endothelial cell [36, 37]. This mes-
enchymal conversion of LECs (Lymph-endo-MT) has not been analysed yet in biopsies of PD 
patients nor in vitro or in vivo studies, and its possible implication in the damage peritoneum 
remains unknown. On the other hand, the adipocytes themselves, apart from their capacity 
to promote a mesenchymal transition in other cells, had been also postulated as a possible 
source of mesenchymal cells in the peritoneal tissue [38, 39].
3. Blood and lymphatic vessels
Blood vessels deliver oxygen and nutrients to cells, whereas lymphatic vessels drain the inter-
stitial fluid that is collected in tissues, and serve as a conduit for immune cell trafficking and fat 
absorption [40]. The correct functionality of both types of vessels is essential for PD treatment as 
it is intimately related to the UF capacity of the PM. An important change in PD is the so-called 
hyalinizing vasculopathy, which consists in the thickening of the wall of the blood peritoneal 
vessels and a luminal narrowing, or even a luminal complete occlusion [41], altering their func-
tionality. Through histology, four degrees of vasculopathy have been defined according to the 
decrease in vessel lumen [42, 43], and its clinical repercussion has not yet been well defined.
New vessels formation is another undesirable consequence of the PD treatment, and this process 
has been observed both in blood and lymphatic vessels, presenting some common inductors.
3.1. Angiogenesis in PD
Angiogenesis is a process characterized by the formation of new capillaries. It supposes an 
increased effective surface area of exchange, which results in a decrease in the glucose-driven 
osmotic pressure of the PDF, favoring the emergence of UFF. Furthermore, the thickening of 
the vascular wall and the increase of permeability cause changes in fluid and solute transport 
in PD patients. In fact, there is an increase in small solute transport and a reduction time for 
exchanging waste products [3].
The major regulator of both physiologic and pathologic angiogenesis is VEGF cytokine. VEGF 
is a potent pro-angiogenic factor that binds to specific receptors on the endothelial cells lining 
blood vessels and that is involved in endothelial cell proliferation and vascular permeability 
[44]. VEGF also stimulates nitric oxide synthase production and the consequent vasodilation, 
and initiates inflammatory responses [45]. The biological activity of VEGF family is mediated 
by three receptors (VEGFRs): VEGFR-1/Flt-1, VEGFR-2/KDR and VEGFR-3/Flt-4. These recep-
tors have an intracellular tyrosine kinase domain that, once activated, leads to the induction 
of different signal transduction pathways [46, 47]. The effect of VEGF is also regulated by a 
family of cell surface glycoproteins called neuropilins (Nrps). This family is composed by 
two members, Nrp-1 and Nrp-2. Nrp-1 has been described as an isoform-specific VEGF co-
receptor expressed in endothelial and tumor cells, enhancing VEGF binding to VEGFR-2 and 
its bioactivity. Nrp-1 may also signal independent of VEGFR-2 in endothelial cells to mediate 
VEGF-triggered migration and adhesion. Moreover, Nrp-1 may also interact with other growth 
factors, such as TGF-β1. Nrp-1 expression has been recently described in many other cell types 
including MCs. In this context, it has been shown that during MMT process of mesothelial cells, 
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there is not only a strong induction of VEGF, but also of Nrp-1. In contrast, the expression of 
the receptors VEGFR-1 and VEGFR-2 is down-regulated. It has also been demonstrated that 
MCs which have undergone an MMT proliferate less and acquire an increased invasion capac-
ity compared with epithelial-like MCs. Furthermore, this enhanced invasion could be partially 
inhibited by treatment with anti-VEGF or anti-Nrp-1b, which strongly suggests that the interac-
tion of VEGF with Nrp-1 may have a role in MCs invasion and PM thickness [47].
The expression of VEGF in human peritoneal mesothelial cells (HPMCs) could be up-regulated 
by several pro-inflammatory cytokines, such as IL-1α and TNF-α. This suggests that intraperito-
neal inflammation might increase peritoneal permeability by inducing angiogenesis [48]. Some 
studies have shown that MCs from omentum have the capacity to produce VEGF in response 
to a variety of stimuli such as GDPs, AGEs or TGF-β. This up-regulation of VEGF in MCs is due 
to the process of MMT. Furthermore, it was found that PD patients with non-epithelioid MCs 
showed increased expression of VEGF compared with those patients with epithelial-like MCs, 
supporting that MMT not only induces fibrosis, but also peritoneal angiogenesis [27].
3.2. Lymphangiogenesis in PD
Another alteration due to PD and associated with inflammation, MMT and peritoneal fibrosis 
is lymphangiogenesis, a process that has been recently recognized as a contributor to peri-
toneal function disorders [9]. Lymphangiogenesis is the growth of lymphatic vessels from 
preexisting vessels, and it is essential in embryonic development but, in adults, it is involved 
in many pathological processes such as lymphedema, metastasis, inflammatory diseases, 
renal transplant rejection, tubule-interstitial fibrosis and also in rat unilateral ureteral obstruc-
tion models [9, 49]. Of note, transient lymphangiogenesis and angiogenesis have also been 
detected during wound healing [50]. Wound healing is a necessary process to repair damage 
but it could convert into a pathological condition when dysregulated, promoting fibrosis and 
vessel formation by secreting cytokines and growth factors.
In PD, lymphatic vessels proliferation with fenestration of the anastomotic mouths is mainly 
visible in the diaphragm (Figure 2). These changes increase the lymphatic absorption rate 
(measured by the rate at which intraperitoneally administered radioactive serum albumin 
or dextran 70 disappears) [9]. Given that the net UF is determined by the effective lymphatic 
absorption and the trans-capillary UF, the increased of lymphatic absorption leads to dimin-
ished UF capacity. This makes it so important to control lymphatic absorption in order to 
obtain higher drained volume [51, 52].
Inflammation is thought to be an important contributor to lymphangiogenesis in human dis-
eases as PD [53]. Particularly, macrophages have been suggested to stimulate lymphangiogen-
esis through the production of VEGF-C and VEGF-D [54]. VEGF-C is one of the most important 
mediators of lymphangiogenesis, and it has been shown that its content in the PD effluent cor-
related with the membrane transport rate [55]. Thus, if VEGF-C concentration in the PD efflu-
ent increases, the PM transport rate will be higher. In other words, there is a positive correlation 
between both factors [9]. Some sources for VEGF-C are pericytes of blood vessels, tumor cells 
and, in inflammatory and neoplastic conditions, tissue macrophages [46, 56, 57].
It has been found that expression of VEGF-C and markers of lymphatic vessels is higher in the 
peritoneum of patients with UFF (in fact, these tissues contain more lymphatic vessels) [9]. 
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However, although the vessel density of non-PD patients is lower than in PD patients, this 
measure did not differ between PD patients with or without UFF. These findings suggest that 
factors other than increased vascular density are involved in disease states associated with 
increased transport of PM [9].
Immuno-histochemical analyses of lymphatic and blood vessels and expression of VEGF-C in 
the peritoneum of patients with UFF or in pre-dialysis situation showed that these elements 
were observed when there is an UFF, but they were hardly detected in the pre-dialysis peri-
toneum. Moreover, expression level of VEGF-C and number of lymphatic vessels correlated 
with one another [9]. In fact, VEGF-C has been shown to be required for a normal develop-
ment of lymphatic vessels [49, 53].
VEGF production is regulated not only by glucose from PDFs, vascular hyper-permeability and 
PD dysfunction, but also by other growth factors and cytokines such as TGF-β [53, 58]. There are 
some studies that have investigated the roles of TGF-β in the progression of lymphangiogenesis 
through VEGF-C induction. In these investigations, the effect of TGF-β1 in VEGF-C expression 
in the human MC line Met-5A and ex vivo cultured HPMCs was studied. The experiments 
showed that VEGF-C (both mRNA expression and protein production) increases in response 
to TGF-β1 treatment in both Met-5A and HPMCs cultures. Moreover, the number of macro-
phages was suppressed by a TGFβR-I inhibitor in a mice model. These findings support that 
TGF-β1 is an important inducer of VEGF-C, leading to lymphangiogenesis that is associated 
Figure 2. (A, B) Mice parietal PMs stained with an anti-CD31 antibody (Abcam, Cambridge, UK). (A) Control sample of 
a saline-treated mouse. (B) PDF-treated mouse with an increased CD31 staining. (C–F) Mice diaphragms stained with 
an anti-podoplanin antibody (PA2.26, from Dr. Gamallo, Laboratory of Pathology, La Princesa Hospital, Madrid, Spain). 
The staining shows the MC monolayer and the lymphatic vessels that drain into the thoracic duct. (C, E) Control sample 
of a saline-treated mouse. (D, F) PDF-treated mouse with a thickening of the PM that covers the peritoneal cavity and a 
proliferation of lymphatic vessels with fenestrated anastomotic mouths. Panels A, B, E, F with 20× magnification. Panels 
C and D with 10× magnification, showing the abdominal (upper) and thoracic sides (down). Figure modified from 
Gonzalez-Mateo et al. (BioMed Research International, 2015; use under http://creativecommons.org/licenses/by/3.0/ for 
CC BY) [33].
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with peritoneal fibrosis in PD patients [9]. Other studies have also demonstrated that TGF-β1 
induced significant up-regulation of VEGF-C expression in cultured human proximal tubular 
epithelial (HK-2) cells, collecting duct (M-1) cells, and macrophages (RAW264.7) [53]. All these 
results could indicate that lymphangiogenesis in the PM is linked with the fibrotic process via 
the TGF-β-VEGF-C pathway [53, 59, 60]. Therefore, prevention of TGF-β induction may reduce 
fibrosis and lymphangiogenesis, resulting in the avoidance of the UFF.
VEGF-D, which is homologous to VEGF-C, is also implicated in the regulation of the peri-
toneal lymphangiogenesis. It had been shown in cultured macrophages and fibroblasts that 
VEGF-D increased by PGE2 and by inflammatory cytokines. However, in contrast to VEGF-C, 
VEGF-D has been reported to be down-regulated by TGF-β. Moreover, although cultured 
human MCs strongly express VEGF-C, they do not express VEGF-D [55]. Either VEGF-C or 
VEGF-D induce growth of the lymphatic vessels via activation of VEGFR-3, which is localized 
on the surface of lymphatic endothelial cells. Signaling via VEGF-C and VEGF-D/VEGFR3 
seems to be the most central pathway for lymphangiogenesis and survival of endothelial cells, 
providing a new therapeutic target to increase net ultrafiltration by suppression of lymphan-
giogenesis and lymphatic absorption. In a murine model of peritoneal injury induced by the 
GDP methylglyoxal (MGO), a precursor of AGEs, VEGFR-3 was up-regulated and the drained 
volume tended to be increased compared with the control group (although not statistically 
significant) [55]. In addition, inhibition of this signaling pathway using an adenovirus express-
ing soluble VEGFR-3 fused with human IgG and using function-blocking antibody entirely 
blocked lymphatic sprouting after infection, but had no effect on blood vessel remodeling [61].
3.3. Endothelial and lymphatic vessels: overlapping markers
As commented before, the lymphatic and blood systems serve different but complementary 
functions to maintain the homeostasis of the tissues. Given that lymphatic endothelial cells 
(LECs) derive from embryonic blood vascular endothelial cells (BECs) during embryogenesis 
[62], it is not surprising that both cell types have some properties and features in common and, 
therefore, share many markers. In this regard, both types of vessels express CD31, CD34, podo-
calyxin, von Willebrand factor and other markers [63]. These facts pose a challenge to distin-
guish both lineages but still there are markers that can be used to differentiate them. Thereby, 
in healthy tissues LECs express specifically podoplanin, the lymphatic vessel endothelial hyal-
uronan receptor (LYVE-1) [64–67], VEGFR-3 [68], and prospero-related homeobox domain 1 
(Prox1) [65, 69]. Prox1 is essential for lymphangiogenesis and helps to drive the expression 
of lymphatic-specific genes that transform venous progenitor cells into functional LECs [40]. 
In fact, it has been demonstrated that loss of Prox1 expression in mice results in arrested lym-
phangiogenesis [70]. Furthermore, the continued expression of Prox1 in LECs of adult animals 
is required for the maintenance of these vessels, as conditional deletion of Prox1 in adult mice 
causes the reversion of lymphatic endothelium to venous endothelium [71].
However, the expression of these markers in healthy LECs may not necessarily apply in the 
lymphatic disease settings [72], so when employing them it is necessary to consider the tissue 
or organ and the possible presence of inflammation or pathological processes. Thus, during 
inflammation, there is an up-regulation of VEGFR-3 on most proliferating blood vessels, which 
makes this marker not useful to distinguish between the lymphatic and blood vessels in this 
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situation [73] (and so during PD exposure, since there is a chronic inflammatory status). In 
regard to podoplanin, this molecule seems to play a role in the pathogenesis of encapsulating 
peritoneal sclerosis (EPS, a severe complication of PD treatments) [74], but is expressed by peri-
toneal mesothelial and fibroblast-like cells [75–78] (Figure 2). It is interesting also to note that 
Prox1 is expressed in normal and pathologic human tissues (lymphedema) [69], but its functions 
are not exclusive to lymphatic vessels, since recent studies have shown that Prox1 is required for 
the development and maintenance of venous valves [79]. In conclusion, to selectively distinguish 
between both types of vessels, a good strategy could be to use a combination of two or more 
markers (accordingly, as an example CD31+/podoplanin cells would be considered as BECs).
Nonetheless, other molecules have recently emerged as potential markers to specifically label 
LECs, but still need confirmation. In this regard, it has been suggested that the Integrin α9, 
a receptor for VCAM-1 (vascular cell adhesion molecule-1), could be a potential marker of 
mouse LECs [80], but it still requires validation since it is not clear whether the application 
of the antibody in human tissues is reliable [72]. Likewise, COLEC 12, a gene that codes for 
Collectin-12 protein (a scavenger receptor), has also been suggested as another LEC marker 
[62]. The expression of CLEVER-1 (common lymphatic endothelial and vascular endothelial 
receptor-1), also known as stabilin-1 or FEEL-1, has been reported in response to inflamma-
tion in skin LECs, macrophages and BECs [81], but also requires to be confirmed as a suitable 
marker for abnormal or diseased human LECs identification [72].
3.4. Specific secretion of cytokines and chemokines
The specialization of endothelial cells extends also to the secretion of biologically relevant 
chemotactic factors. In this regard, LECs, but not BECs, constitutively secrete the chemokine 
receptor CCR7 ligand, secondary lymphoid tissue chemokine (SLC)/CCL21 at their basal side, 
while both subsets, upon activation, release macrophage inflammatory protein (MIP)-3α/
CCL20 apically [63].
4. Therapeutic strategies
Clinical diagnosis is of high value due to the limitations obtaining PM biopsies. Until now, 
procedures include general care actions to avoid fluid overload (use of diuretic agents in 
patients with residual renal function shorten dwell times and volumes of dialysate fluids or 
temporarily discontinue PD) (Table 1). Depending on the UFF type, general recommenda-
tions are as follows.
Regarding the type I UFF, clinical evidence supports the peritoneal resting [82] and the block-
ade of the renin-angiotensin-aldosterone system with angiotensin converting enzyme inhibi-
tors or angiotensin receptor blockers [83, 84]. The use of neutral pH low GDP fluids may be 
beneficial as well, but the evidence to date is inconclusive [85, 86]. With regards to the type II 
UFF, it has been observed that the use at early stages of high doses of steroids or an agonist of 
AQP1 (AqF026) can improve water transport by modulating the expression of AQP1 channels 
[20, 87, 88]. Since the type III PM failure is associated with fibrosis, that in its maximum degree 
leads to EPS, adhesiolysis and peritoneal rest are indicated [89, 90]. Moreover, corticosteroids, 
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azathioprine, mycophenalate, rapamycin and its derivative everolimus have all been tried with 
limited success [91, 92]. More recently, the use of tamoxifen has been reported to be beneficial 
in the treatment of EPS [90, 92, 93]. In this regard, a recent study showed that mortality was 
significantly decreased in patients treated with immunosuppression compared to the group 
with tamoxifen as well [94]. Nutritional support of these patients is also mandatory. The clini-
cal management of liquid overload may be treated with icodextrin PD exchanges at least tem-
porarily. Given the clinical characteristics of PM failure type IV, the long-term absorption of 
dialysate and long dwelling should be included in therapeutic management [14].
But if the treatment is crucial once the UFF is set, what is even more important is to prevent 
this status, what means to focus on the origin of the damage. The use of PD has increased 
over the last years due to the development of different strategies which have allowed the 
improvement of the treatment. During the last years, researchers have been trying to develop 
biocompatible PDFs using new osmotic agents to substitute glucose, such as amino acids or 
icodextrin, to avoid the formation of GDPs and AGEs. However, considering that PDFs of 
new generation are expensive, another alternative is using drugs to treat and prevent perito-
neal damage caused by long exposure to PDFs [95] (Figure 3) (Table 2).
In this context, there are several studies about blocking MMT process, because of its identifica-
tion as a key event in peritoneal damage. These therapeutic strategies were also designed either 
to prevent or reverse the MMT, or to reduce the MMT-inducing stimuli. Nevertheless, it has 
to be taken into account that MMT is a physiologic process necessary for wound healing dur-
ing PD. Another possibility is to act on the consequences of MMT or mesenchymal transition 
of other cells populations instead, such as the increased angiogenesis or lymphangiogenesis 
[33, 47]. The therapeutic options tested until the date are exposed below in detail and summa-
rized in Table 2. These data encourage conducting clinical trials to solidify therapeutic evidences.
4.1. Anti-angiogenic therapy
4.1.1. VEGF
Many studies have been carried out to reduce angiogenesis by the development of angio-
genesis inhibitors which modulate the expression of VEGF, which is a well-known potent 
angiogenic factor associated with vascular proliferation in PD patients. On this line, some 
studies used cyclooxygenase (COX)-2 inhibitors, an induced enzyme that stimulate angiogen-
esis by up-regulation of the expression of VEGF and that is more expressed in non-epithelioid 
cells that had undergone MMT than epithelioid MCs. One of them is Celecoxib, which is able 
to avoid PD-induced angiogenesis in the omentum and parietal peritoneum and to restore UF 
in rat and mice models of standard PDF exposure through an implanted peritoneal catheter. 
Moreover, as COX enzymes are implicated in prostaglandin synthesis too, this treatment was 
also useful decreasing peritoneal inflammation and fibrosis [97, 98].
Another kind of VEGF inhibitors are the tyrosine kinase inhibitors, such as Sunitinib, which is 
able to block the VEGF signaling. Indeed, it has been observed that its administration to a 
female PD patient with end stage renal disease and metastasic renal cell carcinoma helps to 
stabilize the abdominal metastasis as well as the thickness of the PM, and the D/P creatinine 
ratio remains stable [100].
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Endostatin, a 20-kDa C-terminal fragment of type XVIII collagen, has also been described as a 
potent endogenously inhibitor of angiogenesis [102]. Endostatin blocks angiogenesis by directly 
binding to both VEGFR-1 and -2, and blocking VEGF interaction with these receptors, preventing 
all downstream signaling events induced by VEGF [103]. Endostatin also competes with fibro-
nectin, a pro-angiogenic ligand, to bind to its cell surface receptor integrin α
5
β
1
, to interrupt cell 
migration [106]. The anti-angiogenic activity of endostatin has been recently found to be medi-
ated also by its intrinsic ATPase activity in vivo, by inhibiting endothelial cell proliferation, migra-
tion, tube formation and adhesion [130]. Moreover, the therapeutic efficacy of endostatin peptide 
treatment in ameliorating alterations has been demonstrated in a diabetic nephropathy mouse 
model [131] and in a chlorhexidine gluconate (CG)-induced mice peritoneal sclerosis model [105].
Figure 3. Pathways implicated in PM failure and therapeutic options. Numbers in parenthesis correspond with drugs 
tested described in Table 2.
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Route in 
Figure 3
Action Drug Target molecules Processes blocked
Angiogenesis Lymphangiogenesis Fibrosis Others
(1) More bio-compatibility New osmotic agents Receptors of glucose and 
degradation products
Yes [96] Yes [96] Inflammation [96]
(2) COX-2 inhibition Celecoxib VEGF Yes [97, 98] Yes [99] Yes [97, 
98]
Inflammation [97, 98]
(3) Tyrosin-kinase inhibition Sunitinib, Sorafenib 
and Regorafenib
VEGF Yes [100, 101] Yes [101]
(4) Inhibition of VEGF/VEGFR 
pathway and ATPase 
activity
Endostatin VEGF Yes [102, 103] Yes [104] Yes [105] Cell migration [106]
(5) Inhibition of cytokines or 
growth factors/
receptors interaction and 
ECM deposition
Suramin TGFβ and VEGF
α-SMA and FDF
Yes [107] Yes [107] Inflammation [107]
(6) Estrogen receptor 
modulation
Tamoxifen TGFβ, VEGF and leptin Yes [93, 108] Yes [109]
(7) CTGF antagonist FG-3019 VEGF Yes [110]
(8) Inhibition of Rho/ROCK 
pathway
Fasudil
Y-27632
VEGF Yes [111] Yes [111]
(9) TGFβ
blockade
BMP7 TGFβ Yes [112] Yes [112]
Blocking peptides (p17 
and p144)
TGFβ Yes [30] Yes [30]
(10) Vit D receptor activator Calcitriol and 
paricalcitol
TGFβ (and 
inflammatory cells)
Yes [7, 113] Yes rats [114] Yes [7, 
113]
Inflammation [7]
(11) Inhibition of TGFβ/Smad 
pathway
Smad7 TGFβ Yes [115]
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Route in 
Figure 3
Action Drug Target molecules Processes blocked
Angiogenesis Lymphangiogenesis Fibrosis Others
(12) Transketolase activation 
and direct anti-oxidative 
effects
Benfotiamine AGEs Yes [116] Yes [116] Inflammation [116]
(13) PPARγ Rosiglitazone AGEs Yes [117]
(14) Serine protease inhibition Kallistatin VEGF and AGEs Yes [118] Yes [101] Inflammation and 
oxidation [119].
(15) HIF-1α blockade LMWH VEGF and HIF-1α Yes [120] Yes [121] Yes [120] Inflammation [120]. 
Elevate UF [122]
(16) mTOR blockade Rapamycin and 
Everolimus
HIF-1α Yes [33, 123, 
124]
Yes [33, 125, 126]
(17) Oxidative stress reduction N-acetylcysteine TGFβ, VEGF and eNOS, Yes [127] Yes [128]
(18) β1-AR blockade Nebivolol β1-AR Yes [129] Yes [129] Inflammation [129]
Table 2. Drugs already tested to block different pathways implicated in the alterations suffered in the PM during PD treatments. Bibliographic references in brackets.
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Recent investigations reported that Suramin, a polysulfonated naphthylurea, is able to down-reg-
ulate VEGF expression in the peritoneum of a fibrosis rat model induced after CG injection. These 
results suggest that Suramin might inhibit angiogenesis and improve UF by suppressing produc-
tion of angiogenic growth factors such as VEGF. Furthermore, Suramin also inhibited the expres-
sion of TGF-β, α-SMA and the deposition of ECM protein in the peritoneum in this rat model, 
which may indicate that it could be a potent agent for attenuation of peritoneal fibrosis too [107].
Tamoxifen, an estrogen receptor (ER) modulator used for the treatment of breast cancer [132], 
has shown the capacity to affect the expression of the VEGF in mice peritoneal tissue exposed 
to PDF through an access port. As a result, there is a decrease in the number of vessel that 
allows the maintenance of the UF capacity [93]. This decrease may also be due to a down-
regulation of leptin expression, because this molecule can also produce interference in the 
induction of neovascularization [93, 108]. In addition, Tamoxifen has demonstrated to have 
anti-fibrotic activity, being able to inhibit TGF-β1 [109].
It has been found that connective tissue growth factor (CTGF/CCN2), whose expression is 
increased in human fibrotic diseases [133], is required for VEGF-A production in response to TGF-
β1 in fibroblast and mouse peritoneal MCs. In addition, the use of the CTGF antagonist FG-3019 
suppressed the increase in VEGF-A production and peritoneal angiogenesis induced by CG. The 
mechanism by which CTGF is acting remains unknown, but it could be through direct physical 
interactions. However, it seems to be a difference in CTGF action depending on cell type [110].
It has been suggested that the GTPase Rho and its downstream effector Rho-kinase (ROCK), 
that play a leading role in smooth muscle contraction, cell migration, proliferation and gene 
expression [134], may also contribute to development of peritoneal angiogenesis and fibrosis 
induced by PD [135]. In fact, this pathway is able to regulate VEGF expression in endothelial 
cells [136], and the activity of Rho-kinase has been found to be up-regulated in the perito-
neum after PD. For this reason, it has been investigated whether the inhibition of Rho/ROCK 
pathway could have a therapeutic effect on PD-induced angiogenesis and fibrosis. This theory 
has been validated with Fasudil, a Rho-kinase inhibitor, which inhibited peritoneal angiogen-
esis and fibrosis and improved peritoneal function in a rat PD model. This effect may be due 
to the effective reduction of VEGF and TGF-β in the peritoneum [111].
The specific ROCK inhibitor Y-27632 has also shown an effect in preventing tubule-inter-
stitial fibrosis in mice kidneys with unilateral ureteral obstruction [137]. On the other hand, 
the 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly 
known as statins and usually employed as potent inhibitors of cholesterol biosynthesis, 
are also able to inhibit Rho/ROCK pathway through suppressing isoprenylation of small 
RhoGTPases [138], which suggests that statins may have a therapeutic effect on peritoneal 
damage related to PD [139].
4.1.2. Transforming growth factor (TGF)-β
Another strategy to block the process of angiogenesis is to act on the factors that induce the 
expression of VEGF, instead of inhibiting its expression directly. In this context, one of the factors 
that enhance VEGF expression in several cell lines is TGF-β [47, 140]. It has been demonstrated 
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that the administration of TGF-β1-blocking peptides to mice exposed to PDF significantly reduced 
peritoneal angiogenesis and fibrosis [30]. Administration of bone morphogenic protein-7 (BMP-7), 
that antagonizes TGF-β1, reduced new vessel formation in a PDF-exposed rat model [112].
Calcitriol, the most active form of vitamin D, also protected against CG-induced injury in rats 
by decreasing levels of TGF-β and angiotensin II, leading to a decreased peritoneal angiogen-
esis and fibrosis [113]. However, it has to be considered that blocking the action of TGF-β is 
not feasible because it is a pleiotropic factor that regulates several functions and, as a result, 
there may be many side effects [30]. Hence, another possibility could be to identify and act 
over downstream signaling pathways.
On this context, it has been reported that TGF-β exhibits its biological effects through TGF-β/
Smad signaling pathway and that Smad7 negatively regulated the TGF-β induced VEGF [141]. 
Considering this, it has been demonstrated that Smad7 transfection prevents the experimental 
peritoneal angiogenesis by inhibiting the activation of TGF-β/Smad signaling pathway in vivo, 
in a rat model of PD associated with peritoneal fibrosis induced by daily intraperitoneal injec-
tion of Dianeal and intraperitoneal injection of LPS. These results suggest that Smad7 treat-
ment might be an effective therapeutic approach for preventing peritoneal angiogenesis [115].
However, it is important to know that TGFβ is involved in the development and function of 
regulatory T cells (Tregs) [142–144], as adult mice deficient in TGFβ signaling exhibit a defec-
tive Treg phenotype with normal numbers, decreased suppressive function, and an incom-
plete TCR repertoire [145–148]. Tregs cells are extremely important for the maintenance of 
the peritoneal protection during PD [149], so treatments intended to block TGF-β signaling 
should take into account the complete cytokine environment and consider this side effect.
4.1.3. Advanced glycation end products (AGEs)
On the other hand, taking into account that AGEs are another factor leading to peritoneal dam-
age by induced angiogenesis [150], some researchers have focused on the prevention of glucose 
and GDP-induced toxicity. Results showed that the treatment with Benfotiamine, a derivative of 
Vitamin B, brings to a decreased of expression of AGEs and RAGEs in the peritoneum and kidney 
of rats in a uraemic PD model. Moreover, Benfotiamine reduced neovascularization, fibrosis and 
markers of inflammation, leading to an improvement of peritoneal transport in this model [116].
The peroxisome proliferator–activated receptor γ (PPAR-γ) has been also evaluated as a potential 
target to reduce peritoneal damage in PD. Indeed, it has been demonstrated in a mouse PD 
model that the administration of the PPAR- γ agonist rosiglitazone (RSG) is able to diminish 
angiogenesis in vivo, probably by reducing the accumulation of AGEs [117].
Kallistatin, a serine protease inhibitor with anti-inflammatory and anti-oxidative properties, 
has been also recognized as an endogenous anti-angiogenic agent. It may reduce the phos-
phorylation of VEGFR-2 in human umbilical vein endothelial cells, by which it can inhibit 
angiogenesis [118]. It has been recently verified that Kallistatin overexpression in kidney 
tubules of db/db mice inhibited RAGE expression in the diabetic kidney and AGE-stimulated 
cultured proximal tubular cells. Furthermore, there are other mechanisms involved in its reno-
protective effect, such as inhibition of TGF-β pathway or attenuation of oxidative stress [119].
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4.1.4. Hypoxia inducible factor (HIF)-1α
Chronic hypoxia has also been linked to angiogenesis, MMT and fibrosis. One of the fac-
tors that mediate the cellular hypoxic response is the hypoxia inducible factor (HIF)-1α, 
which has demonstrated to play an important role not only in angiogenesis, but also 
in peritoneal fibrosis, extracellular matrix metabolism and inflammatory reaction [120]. 
Recent studies have shown, using a peritoneal fibrosis rat model induced by high glucose, 
that the low molecular weight heparin (LMWH) protects peritoneal structure and function 
through inhibiting the process of angiogenesis, inflammation and fibrosis. These effects of 
LMWH may be due to suppression of HIF-1α expression and its downstream target VEGF 
[120]. In addition, LMWH reduces peritoneal permeability to small solutes and elevates 
UF in PD patients [122]. LMWH has been commonly used until now to diminish fibrin 
deposition and to prevent the occlusion of the peritoneal catheter and intra-abdominal 
adhesion [120].
Rapamycin, an antibiotic with an immune-suppressant activity with pleiotropic effects, 
including anti-angiogenic capacity, is also able to suppress HIF-1α. This anti-angiogenic effect 
is associated with the blockage of the mammalian target of rapamycin (mTOR), because it is an 
upstream activator of HIF-1α. In fact, it has been observed in hypoxic cells that rapamycin can 
interfere with HIF-1α activation by increasing the rate of its degradation [123]. Moreover, the 
anti-angiogenic activity of rapamycin is also due to the decrease in VEGF expression both in 
vitro and in vivo [33, 124], and to the reduction in the response of vascular endothelial cells to 
stimulation by VEGF [124].
4.1.5. Others
Oxidative stress is another factor involved in the changes in PM during PD. It has been 
reported that the reactive oxygen species (ROS) generated by PDF are responsible, at least in 
part, for the PM hyper-permeability and peritoneal fibrosis in vivo. This suggests that antioxi-
dants could be a therapeutic strategy to prevent the damage during long-term PD. In fact, the 
use of the antioxidant N-acetylcysteine (NAC) inhibited the increase of VEGF, TFG-β1 and 
the endothelial NOS (eNOS) [151], which plays a role in the control of vascular tone, perme-
ability and angiogenesis [127, 128].
Blocking β1-adrenergic receptor (β1-AR) expressed in peritoneal MCs is another therapeutic 
strategy to reduce angiogenesis induced during PD [129] since it has been observed that the 
block of this receptor is related with anti-angiogenic effects [152]. Indeed, the β1-AR antag-
onist Nebivolol has demonstrated to attenuate submesothelial vessel formation in a mice 
model of PD obtained by instillation of PDFs through a peritoneal catheter. This effect may be 
associated with its direct interaction with the β1-AR, but it could also be due to the reduction 
of fibrosis and MMT [129].
New studies also have pointed to the possibility that peritoneal adipocytes could also con-
tribute to inflammation and angiogenesis that lead to UFF in PD. That means that targeting 
the changes in adipocytes as well as the secretion of adipokines (or their activation/receptors) 
might provide another therapeutic approach for preventing them [153].
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4.2. Anti-lymphangiogenic therapy
4.2.1. Vitamin D receptor
Despite the fact that Vitamin D analogs have been shown to have anti-angiogenic (as well as 
anti-fibrotic and anti-inflammatory) effects in PD models [7], the potential effects of Vitamin D 
on LECs and lymphangiogenesis remain poorly studied. However, a recent study demonstrates 
that calcitriol attenuated murine LEC tube formation and proliferation in vitro. In addition, 
Paricalcitol significantly decreased lymphangiogenesis in the kidneys of nephrotic rats [114].
4.2.2. Vascular endothelial growth factor (VEGF)
Endostatin, which has been described previously as an anti-angiogenic factor, also exerts anti-
lymphangiogenic effects by competitively inhibition of the interaction between VEGF-C or -D 
and VEGFR-3 in vitro [104]. New drugs have very recently been identified as possible thera-
pies to reduce lymphangiogenesis. LHbisD4, the conjugate of LMWH, has been revealed as a 
potent anti-angiogenic drug that could also suppress the formation of new lymphatic vessels 
by blocking VEGF-C signaling pathway. This drug suppressed the proliferation, migration 
and formation of tubular structures of human dermal LECs in vitro even in the presence of 
high VEGF-C concentrations, and significantly diminished the density of lymphatic vessels in 
primary tumor tissue in breast cancer-bearing mice [121].
Apart from its anti-angiogenic action over blood vasculature previously commented, 
Kallistatin also presents anti-lymphangiogenic properties as it is able to block LECs prolifera-
tion, migration and tube formation. Kallistatin inhibits expression of VEGFR-3 and down-
stream signaling pathways such as phosphorylation of ERK and Akt in LECs [101].
COX-2, VEGF-A, and -C expression levels were elevated in a uraemic rat PD model, show-
ing increased density of CD31+ and LYVE-1+ microvessels in the peritoneum. These changes 
were partially reversed with Celecoxib [99]. In another rat model, intraperitoneal administra-
tion of PDF resulted in increased angiogenesis, lymphangiogenesis, submesothelial matrix 
thickness, and also enhanced expression of mesothelial AQP1 in parietal peritoneal tissues. 
Celecoxib exposure drastically reduced PGE2 levels, angiogenesis, lymphangiogenesis, fibro-
sis and milky spot formation, but did not modify mesothelial AQP1 expression nor VEGF 
tissue expression and inflammatory markers [97].
Many inhibitors of lymphangiogenesis or angiogenesis, such as Sorafenib and Regorafenib, 
are VEGF receptor tyrosine kinase inhibitors, which inhibit the phosphorylation of VEGFR-3, 
while other drugs act by down-regulating the expression of VEGFR-3 [101].
4.2.3. Mammalian target of rapamycin (mTOR)
The specific mTOR inhibitor, rapamycin, has been recently shown to inhibit lymphangiogen-
esis in different studies [125, 126]. Moreover, it shows a protective effect against type I PM 
failure in PD, inhibiting the angiogenesis, lymphangiogenesis and Endo-MT. Furthermore, 
rapamycin also seems to be able to selectively decrease the synthesis and release of the pro-
lymphangiogenic factors VEGF-C and -D in MCs [33].
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4.2.4. Others
N-acetylcysteine has been shown to inhibit tumor angiogenesis and lymphangiogenesis [128] 
due to its antioxidant properties, though it could represent possible therapeutic strategies also 
in PD, although it has not been studied yet.
Tetracycline, minocycline and doxycycline are substances with antibacterial properties, 
which also have other recognized actions that include anti-inflammatory, anti-fibrotic and 
anti-angiogenic effects. This is possibly mediated by NF-κB inhibition [154]. In fact, in an 
ischemic-reperfusion renal rat model, doxycycline showed a prolonged renal function due to 
its protective anti-inflammatory effect [155].
In conclusion, angiogenesis and lymphangiogenesis processes in PD are closely related with 
peritoneal transport alterations, especially PM failure type III and IV. Considering that both 
processes can take place in the early stages, they should be recognized by biochemical mark-
ers in the PD effluent. Therefore, it is important to carry out clinical and basic research in 
order to elucidate the role of both processes in the PM damage and to determine the most 
appropriate therapeutic approach.
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